Study on the Diagnostic Value of Novel PET Molecular Imaging for Renal Cell Carcinoma
Status:
RECRUITING
Trial end date:
2026-05-31
Target enrollment:
Participant gender:
Summary
This study is a diagnostic study. This project aims to explore the clinical application value of PET imaging technologies targeting PSMA, CAIX, and CD70 in renal cell carcinoma. By utilizing PSMA-targeted PET radiopharmaceuticals (e.g., \[Ga\]Ga-PSMA), CAIX-targeted PET radiopharmaceuticals (e.g., \[Ga\]Ga-DOTA-CAIX), and CD70-targeted PET radiopharmaceuticals (e.g., \[Ga\]Ga-NOTA-CD70 antibody fragment) in patients with clinically suspected or confirmed renal cell carcinoma and healthy volunteers, we will investigate their diagnostic and therapeutic potential. \[Ga\]Ga-DOTA-CAIX peptide as an example), and a PET imaging agent targeting CD70 (\[Ga\]Ga-NOTA-CD70 antibody fragment as an example) in patients with clinically suspected or confirmed renal cell carcinoma and healthy volunteers. Integrated PET/MR or PET/CT imaging will be performed to aid in the diagnosis and staging of renal cell carcinoma, assess tumor burden and the expression levels of PSMA, CAIX, and CD70, and assist in determining treatment strategies. Concurrently, preliminary pharmacokinetic analysis of the novel CAIX-targeting molecular probe will be conducted in healthy volunteers to elucidate its metabolic patterns and adverse reactions in vivo.
Phase:
NA
Details
Lead Sponsor:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology